Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Portfolio Pulse from Vandana Singh
Turnstone Biologics Corp. (NASDAQ:TSBX) released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC). The data showed a 25% overall response rate and a 50% disease control rate among four evaluable patients. The company is now focusing on high unmet medical need cancers, including colorectal cancer, head and neck cancer, and uveal melanoma. Despite the promising data, TSBX stock is down 57.53% to 93 cents.
August 15, 2024 | 3:57 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Turnstone Biologics Corp. (NASDAQ:TSBX) released initial data from its Phase 1 STARLING trial of TIDAL-01 in MSS mCRC, showing a 25% overall response rate and a 50% disease control rate. Despite the promising data, TSBX stock is down 57.53% to 93 cents.
The release of initial data from the Phase 1 trial showed mixed results with a 25% overall response rate and a 50% disease control rate. Despite some positive outcomes, the market reacted negatively, leading to a significant drop in stock price. The company's shift in focus to high unmet medical need cancers may provide long-term benefits, but the immediate market reaction is negative.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100